Mathijssen RHJ - Search Results

1

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients.

van Doorn L, Crombag MBS, Rier HN, van Vugt JLA, van Kesteren C, Bins S, Mathijssen RHJ, Levin MD, Koolen SLW. van Doorn L, et al. Among authors: mathijssen rhj. Pharmaceuticals (Basel). 2021 Jan 9;14(1):47. doi: 10.3390/ph14010047. Pharmaceuticals (Basel). 2021. PMID: 33435449 Free PMC article.

2

Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.

van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP. van Doorn L, et al. Thyroid. 2011 Feb;21(2):197-202. doi: 10.1089/thy.2010.0234. Thyroid. 2011. PMID: 21275767

3

Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.

de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L, Wiemer EA, van der Holt B, Verweij J, Mathijssen RH. de Graan AJ, et al. Clin Cancer Res. 2012 Aug 15;18(16):4425-32. doi: 10.1158/1078-0432.CCR-12-0728. Epub 2012 May 29. Clin Cancer Res. 2012. PMID: 22645049

4

Conventional dosing of anticancer agents: precisely wrong or just inaccurate?

Bins S, Ratain MJ, Mathijssen RH. Bins S, et al. Clin Pharmacol Ther. 2014 Apr;95(4):361-4. doi: 10.1038/clpt.2014.12. Clin Pharmacol Ther. 2014. PMID: 24646486 No abstract available.

5

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD. Verheijen RB, et al. Bioanalysis. 2016;8(2):123-34. doi: 10.4155/bio.15.235. Epub 2015 Dec 10. Bioanalysis. 2016. PMID: 26652864

6

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.

Bins S, Eechoute K, Kloth JS, de Man FM, Oosten AW, de Bruijn P, Sleijfer S, Mathijssen RH. Bins S, et al. Clin Pharmacokinet. 2017 Mar;56(3):305-310. doi: 10.1007/s40262-016-0441-0. Clin Pharmacokinet. 2017. PMID: 27461250 Free PMC article.

7

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group. Verheijen RB, et al. Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. doi: 10.1158/1078-0432.CCR-16-1255. Epub 2016 Jul 28. Clin Cancer Res. 2016. PMID: 27470967

8

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.

Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, van Schaik RH, Mathijssen RH. Bins S, et al. Pharmacogenomics. 2016 Sep;17(14):1483-90. doi: 10.2217/pgs-2016-0063. Epub 2016 Aug 17. Pharmacogenomics. 2016. PMID: 27533851

9

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.

Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Yu H, et al. Clin Pharmacokinet. 2017 Mar;56(3):293-303. doi: 10.1007/s40262-016-0443-y. Clin Pharmacokinet. 2017. PMID: 27534647

10

Capecitabine and the Risk of Fingerprint Loss.

van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R. van Doorn L, et al. JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638. JAMA Oncol. 2017. PMID: 27560202 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

421 results

Search Page

Filters